
  
    
      
        Introduction_NNP
        In_IN treating_VBG patients_NNS with_IN severe_JJ sepsis_NN ,_, physicians_NNS are_VBP
        mainly_RB concerned_VBN with_IN biologic_JJ ,_, physiologic_JJ ,_, and_CC clinical_JJ
        outcomes_NNS ._. Of_IN those_DT patients_NNS who_WP survive_VBP to_TO hospital_NN
        discharge_NN ,_, little_JJ is_VBZ known_VBN regarding_VBG their_PRP$ physical_JJ
        functioning_NN (_( ability_NN to_TO conduct_VB activities_NNS of_IN daily_JJ life_NN
        such_JJ as_IN walking_VBG around_IN )_) ,_, psychologic_JJ functioning_NN (_( mental_JJ
        well-being_NN )_) ,_, and_CC social_JJ functioning_NN (_( communication_NN and_CC
        relationships_NNS with_IN others_NNS )_) after_IN sepsis_NN ._. Because_IN '_POS quality_NN
        of_IN life_NN '_'' (_( QoL_NNP )_) describes_VBZ or_CC characterizes_VBZ what_WP the_DT patient_NN
        has_VBZ experienced_VBN as_IN a_DT result_NN of_IN sepsis_NN care_NN ,_, it_PRP is_VBZ a_DT useful_JJ
        and_CC important_JJ supplement_NN to_TO traditional_JJ physiologic_JJ or_CC
        biologic_JJ measures_NNS of_IN health_NN status_NN ;_: that_DT is_VBZ ,_, assessments_NNS of_IN
        effectiveness_NN need_VBP to_TO include_VB wider_JJR measures_NNS of_IN benefits_NNS to_TO
        patients_NNS ,_, and_CC particularly_RB those_DT that_DT measure_NN the_DT impact_NN
        from_IN the_DT patient_NN 's_POS point_NN of_IN view_NN ._. A_DT relevant_JJ therapeutic_JJ
        benefit_NN may_MD also_RB be_VB in_IN restoring_VBG the_DT patient_NN 's_POS ability_NN to_TO
        function_VB on_IN a_DT daily_JJ basis_NN ,_, to_TO socialize_VB ,_, and_CC to_TO be_VB alert_VB ._.
        In_IN fact_NN ,_, a_DT long-term_JJ focus_NN on_IN QoL_NNP in_IN clinical_JJ trial_NN
        evaluations_NNS was_VBD among_IN the_DT recommendations_NNS of_IN a_DT recent_JJ
        sepsis_NN international_JJ advisory_JJ group_NN [_NN 1_CD ]_NN ._.
        This_DT report_NN presents_VBZ the_DT results_NNS of_IN an_DT evaluation_NN of_IN QoL_NNP
        among_IN sepsis_NN survivors_NNS ,_, done_VBN as_IN part_NN of_IN the_DT phase_NN III_NNP
        multicenter_NN KyberSept_NNP trial_NN ._. To_TO the_DT best_JJS of_IN our_PRP$ knowledge_NN ,_,
        limited_JJ information_NN on_IN the_DT effects_NNS of_IN sepsis_NN treatment_NN on_IN
        QoL_NNP has_VBZ been_VBN reported_VBN [_NN 2_CD ,_, 3_CD ]_NN ._. The_DT report_NN focuses_VBZ on_IN the_DT
        effects_NNS of_IN antithrombin_NN (_( AT_NNP )_) III_NNP therapy_NN related_VBN to_TO
        physical_JJ ,_, mental_JJ ,_, and_CC social_JJ functioning_NN of_IN patients_NNS who_WP
        were_VBD randomly_RB assigned_VBN to_TO either_CC high-dose_JJ intravenous_JJ
        treatment_NN with_IN Kybernin_NNP P_NN Â®_NN (_( Aventis_NNP Behring_NNP ,_, Marburg_NNP ,_,
        Germany_NNP ;_: a_DT plasma-derived_JJ AT_NNP III_NNP concentrate_VB ,_, 30_CD ,_, 000_CD IU_NNP
        over_IN 4_CD days_NNS )_) or_CC placebo_NN during_IN up_IN to_TO 90_CD days_NNS of_IN follow_VB up_RB ._.
        In_IN the_DT trial_NN ,_, overall_JJ survival_NN tended_VBD to_TO favor_VB AT_NNP III_NNP over_IN
        placebo_NN after_IN 90_CD days_NNS of_IN follow_VB up_RB ,_, although_IN the_DT
        differences_NNS were_VBD nominal_JJ ._. However_RB ,_, the_DT AT_NNP III_NNP group_NN that_WDT
        did_VBD not_RB receive_VB concomitant_NN heparin_NN exhibited_VBN a_DT nominally_RB
        statistically_RB significant_JJ survival_NN advantage_NN over_IN placebo_NN
        at_IN 90_CD days_NNS of_IN follow-up_JJ ._. The_DT purpose_NN of_IN this_DT investigation_NN
        was_VBD to_TO establish_VB whether_IN these_DT trends_NNS also_RB held_VBN for_IN the_DT
        subjective_JJ effects_NNS of_IN AT_NNP III_NNP in_IN severe_JJ sepsis_NN ._. It_PRP concludes_VBZ
        that_IN AT_NNP III_NNP treatment_NN is_VBZ effective_JJ in_IN improving_VBG long-term_JJ
        patient_NN QoL_NNP ,_, and_CC that_IN future_JJ outcome_NN research_NN studies_NNS of_IN
        severe_JJ sepsis_NN should_MD follow_VB up_RP patients_NNS throughout_IN their_PRP$
        hospital_NN stay_NN and_CC after_IN discharge_NN ._.
      
      
        Method_NNP
        
          Quality_NNP of_IN life_NN instruments_NNS
          There_EX are_VBP a_DT number_NN of_IN important_JJ conceptual_JJ and_CC
          methodologic_JJ issues_NNS in_IN assessing_VBG QoL_NNP in_IN people_NNS who_WP are_VBP
          critically_RB ill_JJ ,_, not_RB least_JJS of_IN which_WDT is_VBZ the_DT question_NN of_IN how_WRB
          it_PRP should_MD be_VB defined_VBN ._. Recent_JJ attempts_NNS to_TO define_VB QoL_NNP have_VBP
          resulted_VBN in_IN the_DT development_NN of_IN a_DT functional_JJ definition_NN
          that_WDT is_VBZ measurable_JJ ,_, evaluable_JJ over_IN time_NN ,_, and_CC readily_RB
          applied_VBN to_TO patients_NNS over_IN a_DT wide_JJ range_NN of_IN illness_NN
          severity_NN ._. Most_JJS attempts_NNS incorporate_VB the_DT domains_NNS of_IN
          physical_JJ ,_, psychologic_JJ /_NN cognitive_JJ ,_, and_CC social_JJ functioning_NN ._.
          Each_DT of_IN these_DT domains_NNS can_MD be_VB measured_VBN in_IN two_CD dimensions_NNS :_:
          objective_NN assessments_NNS of_IN functioning_VBG or_CC health_NN status_NN ;_:
          and_CC more_RBR subjective_JJ perceptions_NNS of_IN general_JJ health_NN ._. The_DT
          patient_NN 's_POS subjective_JJ experience_NN translates_NNS that_WDT objective_NN
          assessment_NN into_IN the_DT actual_JJ QoL_NNP experienced_VBD ._. Thus_RB ,_, where_WRB
          the_DT term_NN '_'' QoL_NNP '_POS is_VBZ used_VBN in_IN the_DT present_JJ study_NN ,_, it_PRP refers_VBZ to_TO
          a_DT composite_NN of_IN objective_NN functional_JJ impairment_NN and_CC
          subjective_JJ perceptions_NNS and_CC expectations_NNS ._. The_DT instruments_NNS
          chosen_VBN for_IN the_DT study_NN were_VBD designed_VBN to_TO reflect_VB this_DT ._.
          QoL_NNP gives_VBZ information_NN on_IN what_WP medical_JJ care_NN has_VBZ
          achieved_VBN for_IN the_DT patient_NN ,_, but_CC severe_JJ sepsis_NN is_VBZ a_DT
          difficult_JJ area_NN in_IN which_WDT to_TO obtain_VB such_JJ information_NN ._.
          Normally_RB ,_, QoL_NNP data_NNS should_MD be_VB obtained_VBN directly_RB from_IN the_DT
          patient_NN ._. Unfortunately_RB ,_, patients_NNS hospitalized_VBN with_IN severe_JJ
          sepsis_NN may_MD be_VB unable_JJ to_TO complete_VB a_DT QoL_NNP measure_NN or_CC it_PRP may_MD
          be_VB too_RB burdensome_JJ ._. Rather_RB than_IN lose_VB information_NN on_IN
          patients_NNS ,_, the_DT physician_NN investigator_NN was_VBD used_VBN as_IN a_DT proxy_NN
          respondent_NN ._.
          Two_CD instruments_NNS were_VBD used_VBN to_TO cover_VB the_DT objective_NN and_CC
          subjective_JJ dimensions_NNS ._. The_DT objective_NN component_NN in_IN the_DT
          study_NN was_VBD measured_VBN using_VBG the_DT Karnofsky_NNP performance_NN scale_NN ._.
          The_DT Karnofsky_NNP scale_NN emphasizes_VBZ physical_JJ performance_NN and_CC
          dependency_NN ;_: it_PRP is_VBZ a_DT descriptive_JJ ,_, ordinal_NN scale_NN that_IN
          ranges_NNS from_IN 100_CD (_( good_JJ health_NN )_) to_TO 0_CD (_( dead_JJ )_) ._. Trial_NN
          investigators_NNS assigned_VBN percentages_NNS based_VBN on_IN physical_JJ
          performance_NN (_( Table_NNP 1_LS )_) ._. The_DT Karnofsky_NNP scale_NN is_VBZ designed_VBN to_TO
          assess_VB independent_JJ functioning_NN and_CC appears_VBZ to_TO have_VB
          substantial_JJ validity_NN as_IN an_DT indicator_NN of_IN overall_JJ physical_JJ
          status_NN ._. The_DT validity_NN and_CC reliability_NN of_IN the_DT scale_NN have_VBP
          been_VBN shown_VBN in_IN several_JJ populations_NNS [_NN 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._.
          The_DT subjective_JJ component_NN of_IN the_DT trial_NN was_VBD measured_VBN
          with_IN multiple_JJ items_NNS using_VBG a_DT visual_JJ analog_NN scale_NN [_NN 7_CD ]_NN ._. A_DT
          visual_JJ analog_NN scale_NN is_VBZ a_DT line_NN with_IN defined_VBN end-points_JJ on_IN
          which_WDT investigators_NNS indicate_VBP a_DT patient_NN 's_POS health_NN state_NN ._.
          Thus_RB ,_, the_DT investigator_NN placed_VBD a_DT mark_NN along_IN a_DT 100_CD mm_NN line_NN
          that_IN best_JJS described_VBN his_PRP$ or_CC her_PRP$ assessment_NN of_IN the_DT patient_NN
          with_IN the_DT domain_NN in_IN question_NN ._. There_EX were_VBD six_CD domains_NNS
          (_( Table_NNP 2_LS )_) ._. The_DT scales_NNS ranged_VBD from_IN 0_CD (_( worst_JJS health_NN status_NN )_)
          to_TO 100_CD (_( best_JJS health_NN status_NN )_) ._. The_DT visual_JJ analog_NN scale_NN has_VBZ
          been_VBN used_VBN in_IN several_JJ studies_NNS of_IN QoL_NNP [_NN 8_CD ,_, 9_CD ,_, 10_CD ]_NN ._.
          Reliability_NNP estimates_NNS for_IN visual_JJ analog_NN scaling_VBG items_NNS
          range_VBP from_IN 0_CD ._. 40_CD to_TO 0_CD ._. 95_CD [_NN 11_CD ]_NN ,_, and_CC these_DT estimates_NNS
          compare_VBP favorably_RB with_IN those_DT for_IN other_JJ scales_NNS [_NN 12_CD ,_,
          13_CD ]_NN ._.
          The_DT six_CD domains_NNS of_IN the_DT first_JJ visual_JJ analog_NN scale_NN and_CC
          the_DT Karnofsky_NNP score_NN are_VBP hereafter_RB referred_VBN to_TO as_IN
          '_POS attributes_VBZ '_'' ._.
        
        
          The_DT clinical_JJ trial_NN
          The_DT KyberSept_NNP trial_NN was_VBD a_DT large_JJ ,_, international_JJ ,_, phase_NN
          III_NNP clinical_JJ trial_NN that_WDT enrolled_VBD 2314_CD patients_NNS who_WP were_VBD
          evaluable_JJ for_IN efficacy_NN and_CC safety_NN in_IN a_DT randomized_JJ ,_,
          double-blind_JJ ,_, placebo-controlled_JJ design_NN in_IN order_NN to_TO
          determine_VB the_DT role_NN of_IN high-dose_JJ AT_NNP III_NNP in_IN patients_NNS with_IN
          severe_JJ sepsis_NN ._. Patients_NNS randomly_RB assigned_VBN to_TO the_DT AT_NNP III_NNP
          group_NN received_VBD a_DT total_NN of_IN 30_CD ,_, 000_CD IU_NNP plasma-derived_JJ ATIII_NNP
          (_( Kybernin_NNP P_NN Â®_NN )_) administered_VBN as_IN a_DT loading_NN dose_NN of_IN 6000_CD IU_NNP
          given_VBN over_IN 30_CD min_NN ,_, followed_VBN by_IN a_DT continuous_JJ infusion_NN of_IN
          6000_CD IU_NNP /_NN day_NN for_IN 4_CD days_NNS ._. The_DT study_NN protocol_NN permitted_VBD
          investigators_NNS to_TO prescribe_VB unfractionated_JJ or_CC
          low-molecular-weight_JJ heparin_NN for_IN venous_JJ thrombosis_NNS
          prophylaxis_NNS (_( â¤_NN 10_CD ,_, 000_CD IU_NNP /_NN day_NN subcutaneous_JJ )_) and_CC heparin_NN
          flushes_NNS for_IN vascular_NN catheter_NN potency_NN (_( â¤_NN 2_CD IU_NNP /_NN kg_NN body_NN
          weight_NN per_IN hour_NN intravenous_JJ )_) ._.
          In_IN the_DT trial_NN ,_, the_DT all-cause_JJ mortality_NN rate_NN at_IN 28_CD days_NNS
          was_VBD almost_RB identical_JJ between_IN the_DT placebo_NN group_NN and_CC the_DT
          group_NN that_WDT received_VBD AT_NNP III_NNP (_( 38_CD ._. 7_CD %_NN versus_CC 39_CD ._. 9_CD %_NN ;_: not_RB
          significant_JJ )_) ._. At_IN the_DT 90_CD -_: day_NN time_NN point_NN ,_, the_DT AT_NNP III_NNP group_NN
          had_VBD a_DT nominally_RB lower_JJR mortality_NN than_IN did_VBD the_DT placebo_NN
          group_NN (_( 46_CD ._. 4_LS %_NN versus_CC 48_CD ._. 5_LS %_NN )_) ._. Among_IN the_DT 680_CD patients_NNS in_IN the_DT
          trial_NN who_WP did_VBD not_RB receive_VB heparin_NN concomitantly_RB ,_, there_EX
          was_VBD a_DT statistically_RB significant_JJ difference_NN between_IN the_DT AT_NNP
          III_NNP and_CC placebo_NN groups_NNS ._. In_IN this_DT subgroup_NN ,_, mortality_NN at_IN 90_CD
          days_NNS in_IN the_DT AT_NNP III_NNP subgroup_NN was_VBD 44_CD ._. 9_CD %_NN ,_, versus_CC 52_CD ._. 5_LS %_NN in_IN
          the_DT placebo_NN subgroup_NN (_( 
          P_NN 
          nominal_JJ =_SYM 0_CD ._. 03_CD )_) ._. A_DT complete_JJ
          description_NN of_IN that_DT study_NN and_CC results_NNS are_VBP reported_VBN
          elsewhere_RB [_NN 14_CD ]_NN ._.
        
        
          Outcomes_NNP
          The_DT Karnofsky_NNP scale_NN and_CC visual_JJ analog_NN scales_NNS were_VBD both_DT
          administered_VBN by_IN physician_NN investigators_NNS when_WRB patients_NNS
          enrolled_VBD in_IN the_DT trial_NN (_( referred_VBD to_TO as_IN '_POS baseline_NN '_'' )_) ;_: during_IN
          the_DT trial_NN at_IN 28_CD days_NNS ,_, 56_CD days_NNS and_CC 90_CD days_NNS after_IN
          enrollment_NN ;_: and_CC at_IN discharge_NN from_IN the_DT hospital_NN (_( if_IN it_PRP
          occurred_VBD other_JJ than_IN at_IN one_CD of_IN those_DT three_CD intervals_NNS )_) ._. For_IN
          example_NN ,_, if_IN a_DT patient_NN survived_VBD and_CC was_VBD discharged_VBN at_IN
          day_NN 60_CD ,_, there_EX would_MD be_VB four_CD assessments_NNS (_( i_NNP ._. e_SYM ._. baseline_NN and_CC
          days_NNS 28_CD ,_, 56_CD ,_, and_CC 60_CD )_) ._. The_DT primary_JJ outcome_NN was_VBD change_NN in_IN
          attribute_VBP scores_NNS until_IN 90_CD days_NNS after_IN patients_NNS were_VBD
          assigned_VBN to_TO either_CC treatment_NN or_CC placebo_NN ._. For_IN this_DT
          analysis_NN ,_, two_CD patient_NN populations_NNS were_VBD used_VBN ._. The_DT smaller_JJR
          population_NN was_VBD the_DT group_NN remaining_VBG in_IN the_DT hospital_NN 90_CD
          days_NNS from_IN baseline_NN -_: the_NNP '_POS in-hospital_JJ survivors_NNS '_'' ._. The_DT
          larger_JJR population_NN comprised_VBN all_DT survivors_NNS at_IN 90_CD days_NNS ,_, or_CC
          at_IN the_DT time_NN point_NN closest_JJS to_TO 90_CD days_NNS ._. This_DT group_NN is_VBZ
          labeled_VBN the_NNP '_POS all-survivors_JJ '_POS group_NN ._. It_PRP includes_VBZ the_DT
          in-hospital_JJ group_NN ._. In_IN cases_NNS in_IN which_WDT there_EX was_VBD no_DT patient_NN
          response_NN at_IN 90_CD days_NNS because_IN they_PRP had_VBD been_VBN discharged_VBN ,_, the_DT
          data_NNS from_IN the_DT last_JJ assessment_NN but_CC before_IN 90_CD days_NNS were_VBD
          used_VBN ._. This_DT method_NN is_VBZ equivalent_JJ to_TO using_VBG the_DT last_JJ
          observation_NN carried_VBD forward_RB ._.
          The_DT last_JJ observation_NN carried_VBD forward_RB method_NN uses_VBZ the_DT
          last_RB observed_JJ value_NN for_IN that_DT case_NN ,_, and_CC it_PRP therefore_RB
          assumes_VBZ that_IN the_DT outcome_NN remains_VBZ constant_JJ at_IN the_DT last_RB
          observed_JJ value_NN after_IN discharge_NN ._. Otherwise_RB stated_VBN ,_, it_PRP is_VBZ
          assumed_VBN that_IN QoL_NNP in_IN sepsis_NN patients_NNS is_VBZ stable_JJ on_IN average_NN
          for_IN the_DT short_JJ time_NN period_NN between_IN discharge_NN and_CC 90_CD days_NNS ._.
          It_PRP is_VBZ not_RB possible_JJ to_TO conclude_VB firmly_RB that_IN the_DT change_NN in_IN
          QoL_NNP between_IN discharge_NN and_CC 90_CD days_NNS was_VBD small_JJ and_CC unbiased_JJ ._.
          However_RB ,_, the_DT fact_NN that_IN the_DT hospital_NN discharge_NN curve_NN
          between_IN AT_NNP III_NNP and_CC placebo_NN was_VBD almost_RB identical_JJ provides_VBZ
          evidence_NN that_IN the_DT comparison_NN between_IN treatment_NN groups_NNS
          should_MD be_VB unbiased_JJ ._. Moreover_RB ,_, the_DT physician_NN investigator_NN ,_,
          the_DT patient_NN ,_, and_CC the_DT family_NN were_VBD blinded_JJ to_TO the_DT treatment_NN
          assignment_NN (_( placebo_NN versus_CC AT_NNP III_NNP )_) throughout_IN the_DT
          duration_NN of_IN the_DT clinical_JJ trial_NN ._.
          The_DT secondary_JJ outcome_NN was_VBD change_NN in_IN the_DT attribute_NN
          scores_NNS at_IN 28_CD ,_, 56_CD ,_, and_CC 90_CD days_NNS after_IN assignment_NN to_TO
          treatment_NN or_CC placebo_NN ._. That_DT outcome_NN measure_NN was_VBD used_VBN in_IN
          order_NN to_TO compare_VB relative_JJ changes_NNS between_IN AT_NNP III_NNP and_CC
          placebo_NN groups_NNS at_IN the_DT 28_CD -_: day_NN ,_, 56_CD -_: day_NN ,_, and_CC 90_CD -_: day_NN
          assessments_NNS ._.
        
        
          Analysis_NNP
          
            Patient_NNP characteristics_NNS
            Mean_VB ,_, standard_JJ deviation_NN ,_, and_CC range_NN values_NNS (_( for_IN age_NN )_)
            and_CC percentages_NNS for_IN relevant_JJ patient_NN characteristics_NNS
            (_( at_IN enrollment_NN and_CC administration_NN of_IN heparin_NN )_) are_VBP
            reported_VBN ._. The_DT overall_JJ trial_NN population_NN is_VBZ presented_VBN ,_, as_RB
            well_RB as_IN the_DT all-survivors_JJ and_CC the_DT in-hospital_JJ survivors_NNS
            groups_NNS ._. The_DT other_JJ variables_NNS used_VBN were_VBD Simplified_NNP Acute_NNP
            Physiology_NNP Score_NN (_( SAPS_NNP )_) II_NNP [_NN 15_CD ]_NN (_( a_DT measure_NN of_IN severity_NN
            of_IN illness_NN )_) ,_, admitting_VBG diagnosis_NN ,_, and_CC concomitant_NN use_NN
            of_IN heparin_NN ._. In_IN the_DT SAPS_NNP II_NNP system_NN ,_, a_DT score-to-risk_JJ
            transformation_NN developed_VBN by_IN Le_NNP Gall_NNP 
            et_CC al_NN ._. [_NN 16_CD ]_NN for_IN sepsis_NN patients_NNS
            was_VBD used_VBN ._. The_DT risk_NN intervals_NNS were_VBD identical_JJ to_TO the_DT SAPS_NNP
            II_NNP strata_NN defined_VBN in_IN the_DT trial_NN ._.
          
          
            Changes_NNS in_IN quality_NN of_IN life_NN between_IN baseline_NN and_CC
            90_CD days_NNS
            For_IN both_DT the_DT in-hospital_JJ survivors_NNS and_CC the_DT
            all-survivors_JJ groups_NNS ,_, mean_VB changes_NNS and_CC standard_JJ
            deviations_NNS between_IN baseline_NN and_CC 90_CD days_NNS are_VBP shown_VBN ._.
            Differences_NNS in_IN QoL_NNP between_IN AT_NNP III_NNP and_CC placebo_NN were_VBD
            estimated_VBN for_IN each_DT attribute_VBP ._. Two-sample_NNP Wilcoxon_NNP
            statistical_JJ tests_NNS were_VBD used_VBN to_TO determine_VB whether_IN the_DT
            changes_NNS were_VBD different_JJ between_IN treatment_NN groups_NNS ._.
          
          
            Differences_NNS among_IN patient_NN subgroups_NNS
            Similarly_RB ,_, Wilcoxon_NNP tests_NNS were_VBD used_VBN to_TO identify_VB
            whether_IN changes_NNS in_IN the_DT QoL_NNP scores_NNS differed_VBD for_IN
            subgroups_NNS between_IN baseline_NN and_CC 90_CD days_NNS ._. This_DT analysis_NN
            was_VBD done_VBN on_IN the_DT all-survivors_JJ population_NN ._.
          
          
            Changes_NNS in_IN quality_NN of_IN life_NN between_IN baseline_NN and_CC
            28_CD ,_, 56_CD ,_, and_CC 90_CD days_NNS
            For_IN the_DT all-survivors_JJ and_CC in-hospital_JJ survivors_NNS
            subgroups_NNS ,_, comparative_JJ differences_NNS in_IN changes_NNS between_IN
            baseline_NN and_CC 28_CD ,_, 56_CD ,_, and_CC 90_CD days_NNS were_VBD estimated_VBN ._. For_IN
            each_DT attribute_VBP ,_, the_DT difference_NN in_IN mean_NN change_NN between_IN
            treatment_NN groups_NNS is_VBZ presented_VBN ,_, together_RB with_IN two-sided_JJ
            95_CD %_NN confidence_NN intervals_NNS ,_, so_IN that_IN the_DT differences_NNS
            between_IN placebo_NN and_CC AT_NNP III_NNP over_IN time_NN are_VBP clearly_RB
            shown_VBN ._.
          
          
            Statistical_NNP considerations_NNS
            Nominal_NNP 
            P_NN values_NNS should_MD be_VB regarded_VBN as_IN
            descriptive_JJ because_IN no_DT formal_JJ null_NN hypothesis_NNS was_VBD
            prespecified_JJ and_CC no_DT type_NN I_PRP error_NN probability_NN can_MD be_VB
            indicated_VBN ._. No_DT adjustment_NN of_IN 
            P_NN values_NNS for_IN multiple_JJ testing_NN or_CC
            multiple_JJ confidence_NN intervals_NNS was_VBD made_VBN ._. 
            P_NN values_NNS less_JJR than_IN or_CC equal_JJ to_TO
            0_CD ._. 05_CD were_VBD considered_VBN statistically_RB significant_JJ ._. 
            P_NN values_NNS above_IN 0_CD ._. 05_CD but_CC less_JJR than_IN
            or_CC equal_JJ to_TO 0_CD ._. 10_CD were_VBD considered_VBN indicative_JJ of_IN a_DT trend_NN ._.
            Confidence_NN intervals_NNS for_IN the_DT difference_NN between_IN mean_NN
            changes_NNS were_VBD constructed_VBN assuming_VBG a_DT normal_JJ distribution_NN
            of_IN changes_NNS from_IN baseline_NN ._.
          
        
      
      
        Results_NNS
        
          Patient_NNP characteristics_NNS
          Table_NNP 3_CD shows_VBZ baseline_NN patient_NN demographic_JJ data_NNS and_CC
          heparin_NN administration_NN for_IN the_DT 2314_CD patients_NNS who_WP entered_VBD
          the_DT KyberSept_NNP trial_NN ._. The_DT all-survivors_JJ group_NN using_VBG the_DT
          last_JJ observation_NN carried_VBD forward_RB analysis_NN totaled_VBD 897_CD
          patients_NNS ,_, whereas_IN the_DT in-hospital_JJ group_NN totaled_VBD 118_CD ._. The_DT
          patients_NNS included_VBN in_IN this_DT study_NN population_NN were_VBD from_IN a_DT
          broad_JJ mixture_NN of_IN countries_NNS ._.
          The_DT mean_JJ Â±_NN SD_NNP age_NN of_IN the_DT overall_JJ population_NN was_VBD 58_CD Â±_NN
          17_CD years_NNS in_IN the_DT placebo_NN group_NN and_CC 57_CD Â±_NN 17_CD years_NNS in_IN the_DT AT_NNP
          III_NNP group_NN ._. Mean_VB age_NN was_VBD lower_JJR (_( 53_CD Â±_NN 17_CD years_NNS )_) in_IN the_DT
          all-survivors_JJ population_NN ._. A_DT clear_JJ majority_NN of_IN patients_NNS
          were_VBD men_NNS (_( 61_CD ._. 5_LS %_NN men_NNS versus_CC 38_CD ._. 5_LS %_NN women_NNS )_) ._. In_IN the_DT three_CD
          populations_NNS (_( overall_JJ ,_, all_DT 90_CD day_NN survivors_NNS ,_, and_CC 90_CD day_NN
          in-hospital_JJ survivors_NNS )_) ,_, the_DT sex_NN distribution_NN for_IN the_DT AT_NNP
          III_NNP groups_NNS was_VBD similar_JJ ._. There_EX was_VBD a_DT shift_NN toward_IN the_DT
          lower_JJR risk_NN strata_NN of_IN SAPS_NNP II_NNP score_NN from_IN the_DT overall_JJ
          population_NN to_TO the_DT all-survivors_JJ population_NN ,_, whereas_IN the_DT
          risks_NNS in_IN the_DT in-hospital_JJ population_NN were_VBD slightly_RB higher_JJR
          than_IN those_DT in_IN the_DT overall_JJ population_NN ._. In_IN the_DT
          all-survivors_JJ group_NN respiratory_JJ disorders_NNS were_VBD the_DT most_RBS
          common_JJ diagnostic_JJ admitting_VBG category_NN ,_, whereas_IN digestive_JJ
          causes_NNS of_IN sepsis_NN were_VBD the_DT most_RBS common_JJ among_IN the_DT
          in-hospital_JJ group_NN ._.
          Among_IN all_DT patients_NNS enrolled_VBD in_IN the_DT trial_NN ,_, 70_CD %_NN received_VBD
          heparin_NN concomitantly_RB ._. Among_IN the_DT all-survivors_JJ ,_, placebo_NN
          and_CC AT_NNP III_NNP differed_VBD by_IN 3_CD %_NN with_IN respect_NN to_TO concomitant_NN
          heparin_NN administration_NN ._. In_IN this_DT population_NN 71_CD %_NN of_IN placebo_NN
          patients_NNS were_VBD administered_VBN heparin_NN concomitantly_RB ;_: 68_CD %_NN of_IN
          those_DT administered_VBN AT_NNP III_NNP received_VBD heparin_NN ._. Among_IN the_DT
          in-hospital_JJ survivors_NNS at_IN 90_CD days_NNS ,_, 87_CD %_NN in_IN the_DT placebo_NN
          group_NN received_VBD heparin_NN as_IN compared_VBN with_IN 70_CD %_NN of_IN those_DT
          receiving_VBG AT_NNP III_NNP ._. Comparing_VBG AT_NNP III_NNP groups_NNS across_IN
          populations_NNS ,_, the_DT use_NN of_IN concomitant_NN heparin_NN was_VBD nearly_RB
          the_DT same_JJ ._.
        
        
          Changes_NNS in_IN 90_CD -_: day_NN quality_NN of_IN life_NN
          Table_NNP 4_CD shows_VBZ data_NNS for_IN the_DT six_CD attributes_NNS of_IN the_DT visual_JJ
          analog_NN scale_NN and_CC the_DT Karnofsky_NNP scale_NN (_( objective_NN physical_JJ
          performance_NN and_CC dependency_NN )_) measured_VBN from_IN baseline_NN to_TO 90_CD
          days_NNS ._. Assessment_NNP of_IN the_DT changes_NNS among_IN the_DT all-survivors_JJ ,_,
          based_VBN on_IN two-sided_JJ ,_, two-sample_JJ Wilcoxon_NNP tests_NNS ,_, suggests_VBZ
          advantages_NNS for_IN the_DT AT_NNP III_NNP group_NN as_IN compared_VBN with_IN the_DT
          placebo_NN group_NN in_IN three_CD of_IN the_DT attributes_NNS ;_: namely_RB ,_, patient_NN
          communication_NN and_CC speech_NN ,_, level_NN of_IN alertness_NNS ,_, and_CC energy_NN
          level_NN ._. In_IN the_DT inhospital_NN population_NN ,_, the_DT differences_NNS
          indicated_VBD that_DT communication_NN and_CC speech_NN ,_, level_NN of_IN
          alertness_NNS ,_, and_CC the_DT Karnofsky_NNP scale_NN were_VBD all_DT more_RBR improved_JJ
          for_IN the_DT AT_NNP III_NNP group_NN than_IN for_IN placebo_NN ._.
          In_IN neither_DT population_NN was_VBD the_DT change_NN in_IN patient_NN
          overall_JJ QoL_NNP judged_VBN to_TO be_VB statistically_RB different_JJ ._. In_IN the_DT
          in-hospital_JJ group_NN ,_, a_DT trend_NN toward_IN greater_JJR patient_NN energy_NN
          levels_NNS in_IN the_DT AT_NNP III_NNP group_NN was_VBD found_VBN (_( 
          P_NN <_NN 0_CD ._. 10_CD )_) ._.
        
        
          Differences_NNS across_IN patient_NN subgroups_NNS
          As_IN shown_VBN in_IN Table_NNP 5_CD ,_, although_IN there_EX were_VBD generally_RB
          greater_JJR increases_NNS in_IN attribute_VBP scores_NNS in_IN the_DT SAPS_NNP II_NNP risk_NN
          for_IN AT_NNP III_NNP in_IN the_DT all-survivors_JJ ,_, none_NN of_IN the_DT differences_NNS
          were_VBD statistically_RB significant_JJ ._. There_EX were_VBD also_RB no_DT
          significant_JJ differences_NNS between_IN placebo_NN and_CC AT_NNP III_NNP
          according_VBG to_TO the_DT diagnostic_JJ subgroups_NNS on_IN hospital_NN
          admission_NN ,_, although_IN a_DT few_JJ '_POS trends_NNS '_POS favoring_VBG AT_NNP III_NNP
          (_( notably_RB the_NNP '_POS energy_NN level_NN '_'' attribute_NN of_IN QoL_NNP )_) were_VBD found_VBN ._.
          In_IN the_DT heparin_NN subgroups_NNS ,_, there_EX was_VBD an_DT advantage_NN in_IN some_DT
          attributes_VBZ for_IN AT_NNP III_NNP ._. Compared_VBN with_IN placebo_NN ,_, physical_JJ
          activity_NN was_VBD improved_VBN significantly_RB more_JJR in_IN the_DT AT_NNP III_NNP
          subgroup_NN than_IN in_IN the_DT placebo_NN subgroup_NN not_RB receiving_VBG
          heparin_NN ._. There_EX was_VBD also_RB a_DT trend_NN toward_IN greater_JJR
          improvement_NN in_IN three_CD other_JJ attributes_NNS in_IN the_DT no_DT
          concomitant_NN heparin_NN subgroup_NN ,_, namely_RB patient_NN mobility_NN ,_,
          communication_NN and_CC speech_NN ,_, and_CC patient_NN energy_NN level_NN ._.
          Excluding_VBG the_DT Karnofsky_NNP scores_NNS that_WDT were_VBD unchanged_JJ ,_, mean_VB
          nominal_JJ changes_NNS in_IN the_DT AT_NNP III_NNP QoL_NNP attributes_NNS of_IN the_DT no_DT
          concomitant_NN heparin_NN group_NN ranged_VBD from_IN +_NN 4_CD to_TO +_NN 9_CD ,_, whereas_IN
          those_DT receiving_VBG concomitant_NN heparin_NN experienced_VBD nominal_JJ
          increases_NNS in_IN scores_NNS ranging_VBG from_IN +_NN 2_CD to_TO +_NN 5_CD ._.
        
        
          Changes_NNS in_IN quality_NN of_IN life_NN between_IN baseline_NN and_CC 28_CD ,_,
          56_CD ,_, and_CC 90_CD days_NNS
          Figs_NNP 1_CD and_CC 2_CD show_NN the_DT differences_NNS in_IN mean_NN changes_NNS in_IN
          scores_NNS between_IN baseline_NN and_CC later_RB periods_NNS for_IN the_DT seven_CD
          attributes_VBZ measured_VBN in_IN the_DT AT_NNP III_NNP group_NN as_IN compared_VBN with_IN
          placebo_NN ._. Fig_NNP ._. 1_LS shows_VBZ results_NNS for_IN the_DT all-survivors_JJ
          population_NN ,_, whereas_IN Fig_NNP ._. 2_LS shows_VBZ findings_NNS in_IN the_DT
          in-hospital_JJ population_NN ._. Considering_VBG point_NN estimates_NNS of_IN
          differences_NNS between_IN mean_NN changes_NNS at_IN each_DT time_NN point_NN ,_, for_IN
          all_DT attributes_VBZ and_CC in_IN both_DT populations_NNS AT_NNP III_NNP patients_NNS
          were_VBD more_RBR improved_JJ than_IN placebo_NN patients_NNS ._. Confidence_NN
          intervals_NNS fully_RB occupying_VBG the_NNP '_POS AT_NNP III_NNP better_JJR '_POS side_NN
          indicate_VBP statistically_RB significant_JJ improvements_NNS in_IN the_DT AT_NNP
          III_NNP group_NN ._. In_IN the_DT all-survivors_JJ population_NN ,_, comparative_JJ
          improvements_NNS tended_VBD to_TO increase_VB over_IN time_NN in_IN the_DT AT_NNP III_NNP
          group_NN as_IN compared_VBN with_IN the_DT placebo_NN group_NN ._. An_DT exception_NN
          was_VBD the_DT Karnofsky_NNP index_NN ,_, for_IN which_WDT the_DT difference_NN between_IN
          treatment_NN groups_NNS remained_VBD approximately_RB constant_JJ over_IN
          time_NN ._. For_IN the_DT in-hospital_JJ population_NN ,_, the_DT advantage_NN in_IN
          the_DT AT_NNP III_NNP group_NN increased_VBD over_IN time_NN for_IN the_DT
          communication_NN /_NN speech_NN and_CC the_DT level_NN of_IN alertness_NNS
          attributes_VBZ ,_, whereas_IN the_DT difference_NN between_IN treatment_NN
          groups_NNS remained_VBD approximately_RB constant_JJ for_IN the_DT other_JJ
          attributes_NNS ._. In_IN the_DT all-survivors_JJ ,_, the_DT greatest_JJS
          comparative_JJ advantages_NNS for_IN the_DT AT_NNP III_NNP group_NN were_VBD found_VBN in_IN
          communication_NN /_NN speech_NN ,_, alertness_NNS ,_, and_CC energy_NN level_NN ._.
        
      
      
        Discussion_NNP
        The_DT present_JJ study_NN represents_VBZ the_DT first_JJ attempt_NN to_TO
        evaluate_VB patient_NN QoL_NNP over_IN a_DT relatively_RB long_JJ period_NN in_IN a_DT
        large_JJ ,_, randomized_JJ ,_, placebo-controlled_JJ sepsis_NN trial_NN ._. The_DT
        results_NNS of_IN the_DT study_NN indicate_VBP that_IN ,_, over_IN a_DT 90_CD -_: day_NN period_NN ,_,
        survivors_NNS of_IN severe_JJ sepsis_NN receiving_VBG AT_NNP III_NNP experienced_VBD
        substantial_JJ and_CC statistically_RB significant_JJ improvements_NNS as_IN
        compared_VBN with_IN placebo_NN in_IN several_JJ attributes_NNS of_IN QoL_NNP ._. These_DT
        results_NNS held_VBN for_IN both_DT all-survivors_JJ and_CC in-hospital_JJ
        survivors_NNS populations_NNS ._. The_DT comparative_JJ advantage_NN in_IN QoL_NNP for_IN
        AT_NNP III_NNP was_VBD also_RB maintained_VBN from_IN 28_CD to_TO 56_CD ,_, and_CC 90_CD days_NNS ._.
        After_IN 90_CD days_NNS ,_, the_DT study_NN also_RB found_VBD an_DT advantage_NN with_IN AT_NNP
        III_NNP for_IN some_DT attributes_VBZ in_IN patients_NNS who_WP did_VBD not_RB receive_VB
        heparin_NN concomitantly_RB ._.
        The_DT improvements_NNS identified_VBN in_IN the_DT study_NN should_MD be_VB
        interpreted_VBN in_IN terms_NNS of_IN statistical_JJ and_CC clinical_JJ
        significance_NN ._. Clinical_NNP significance_NN deals_NNS with_IN the_DT applied_VBN
        value_NN of_IN the_DT change_NN in_IN everyday_JJ life_NN ._. Unfortunately_RB ,_, as_IN
        with_IN most_JJS other_JJ QoL_NNP instruments_NNS ,_, there_EX is_VBZ not_RB yet_RB a_DT clear_JJ
        standard_NN for_IN '_POS minimal_JJ clinically_RB important_JJ differences_NNS '_'' ._.
        However_RB ,_, improvements_NNS by_IN approximately_RB 20_CD %_NN in_IN the_DT
        in-hospital_JJ group_NN of_IN AT_NNP III_NNP sepsis_NN patients_NNS after_IN 90_CD days_NNS
        in_IN communication_NN /_NN speech_NN and_CC level_NN of_IN alertness_NNS probably_RB
        represent_VBP meaningful_JJ improvements_NNS in_IN many_JJ patients_NNS ._.
        Another_DT limitation_NN of_IN the_DT present_JJ study_NN is_VBZ the_DT fact_NN that_IN
        investigators_NNS were_VBD proxy_NN respondents_NNS ,_, rather_RB than_IN patients_NNS
        responding_VBG themselves_PRP ._. Like_IN many_JJ studies_NNS of_IN QoL_NNP in_IN critical_JJ
        care_NN settings_NNS ,_, physicians_NNS were_VBD assumed_VBN to_TO be_VB sufficiently_RB
        close_RB to_TO patients_NNS to_TO provide_VB valid_JJ and_CC reliable_JJ data_NNS ._.
        Although_IN this_DT was_VBD not_RB substantiated_JJ empirically_RB ,_, there_EX is_VBZ
        usually_RB moderate_JJ agreement_NN between_IN patients_NNS and_CC proxies_NNS ,_,
        although_IN lower_JJR levels_NNS of_IN agreement_NN have_VBP been_VBN found_VBN in_IN
        psychosocial_NN functioning_VBG [_NN 17_CD ,_, 18_CD ]_NN ._.
      
      
        Conclusion_NNP
        Combined_VBN with_IN previous_JJ findings_NNS in_IN 90_CD -_: day_NN mortality_NN for_IN
        those_DT without_IN concomitant_NN administration_NN of_IN heparin_NN ,_, this_DT
        multinational_JJ study_NN demonstrates_VBZ that_IN AT_NNP III_NNP is_VBZ associated_VBN
        with_IN meaningful_JJ improvements_NNS in_IN health_NN for_IN many_JJ sepsis_NN
        patients_NNS over_IN an_DT extended_VBN 3_CD -_: month_NN follow-up_JJ period_NN ._. In_IN this_DT
        subgroup_NN ,_, the_DT clinical_JJ improvements_NNS over_IN a_DT long_JJ time_NN period_NN
        in_IN patients_NNS in_IN the_DT AT_NNP III_NNP group_NN were_VBD complemented_JJ by_IN
        improvements_NNS in_IN QoL_NNP in_IN many_JJ patients_NNS ,_, particularly_RB in_IN terms_NNS
        of_IN social_JJ and_CC psychologic_JJ functioning_NN ._. Although_IN no_DT
        significant_JJ reduction_NN in_IN 90_CD -_: day_NN mortality_NN was_VBD found_VBN for_IN the_DT
        overall_JJ population_NN ,_, a_DT nominal_JJ advantage_NN in_IN mortality_NN for_IN
        the_DT AT_NNP III_NNP group_NN combined_VBN with_IN a_DT generally_RB improved_VBN QoL_NNP
        profile_NN in_IN the_DT survivors_NNS of_IN this_DT group_NN suggests_VBZ a_DT possible_JJ
        long-term_JJ benefit_NN from_IN AT_NNP III_NNP ._. Future_JJ studies_NNS of_IN critically_RB
        ill_JJ patients_NNS with_IN severe_JJ sepsis_NN or_CC other_JJ conditions_NNS should_MD
        include_VB long-term_JJ follow_VB up_RB of_IN patients_NNS throughout_IN
        hospitalization_NN and_CC after_IN hospital_NN discharge_NN ._. In_IN sepsis_NN ,_,
        long-term_JJ follow_VB up_RB appears_VBZ to_TO provide_VB more_RBR meaningful_JJ
        outcome_NN data_NNS for_IN patients_NNS ,_, families_NNS ,_, and_CC society_NN than_IN do_VBP
        standard_JJ 28_CD -_: day_NN ,_, all-cause_JJ mortality_NN statistics_NNS ._.
      
      
        Key_JJ messages_NNS
        Â·_NN In_IN the_DT present_JJ study_NN ,_, clinical_JJ improvements_NNS over_IN an_DT
        extended_VBN time_NN period_NN with_IN AT_NNP III_NNP were_VBD complemented_JJ by_IN
        improvements_NNS in_IN QoL_NNP ,_, particularly_RB in_IN social_JJ andpsychologic_JJ
        functioning_NN ,_, in_IN a_DT predefined_JJ subgroup_NN of_IN patients_NNS who_WP did_VBD
        not_RB receive_VB heparin_NN ._.
        Â·_NN Combined_VBN with_IN previous_JJ research_NN on_IN 90_CD -_: day_NN mortality_NN ,_,
        the_DT study_NN suggests_VBZ that_IN AT_NNP III_NNP may_MD confer_VB long-term_JJ benefit_NN
        in_IN sepsis_NN patients_NNS ._.
        Â·_NN Among_IN the_NNP '_POS all_DT survivors_NNS '_POS group_NN of_IN patients_NNS ,_,
        communication_NN and_CC speech_NN ,_, level_NN of_IN alertness_NNS ,_, and_CC energy_NN
        level_NN exhibited_VBN the_DT greatest_JJS gains_NNS at_IN 90_CD days_NNS ._.
        Â·_NN In_IN most_JJS cases_NNS ,_, significant_JJ differences_NNS in_IN patient_NN QoL_NNP
        scores_NNS at_IN 90_CD days_NNS after_IN hospital_NN admission_NN were_VBD also_RB found_VBN
        at_IN the_DT 28_CD -_: day_NN and_CC 56_CD -_: day_NN assessments_NNS ._.
        Â·_NN Future_NNP studies_NNS in_IN patients_NNS with_IN severe_JJ sepsis_NN should_MD
        include_VB long-term_JJ follow_VB up_RB throughout_IN hospitalization_NN and_CC
        after_IN hospital_NN discharge_NN ._.
      
      
        Competing_VBG interests_NNS
        Dale_NNP Rublee_NNP ,_, Heinz-_NNP Otto_NNP Keinecke_NNP ,_, and_CC Sigrid_NNP Knaub_NNP are_VBP
        employees_NNS of_IN Aventis_NNP Behring_NNP ,_, the_DT latter_NN also_RB owning_VBG
        Aventis_NNP stock_NN options_NNS ._. Steven_NNP Opal_NNP is_VBZ supported_VBN by_IN a_DT grant_NN
        from_IN the_DT Genetics_NNP Institute_NNP ,_, Cambridge_NNP ,_, MA_NNP ._. He_PRP also_RB is_VBZ
        principal_JJ investigator_NN in_IN the_DT PAF_NNP Acetylhydorolase_NNP study_NN
        carried_VBD out_IN by_IN ICOS_NNP ,_, Bothell_NNP ,_, WA_NNP ._.
      
      
        Abbreviations_NNP
        AT_NNP =_SYM antithrombin_NN ;_: QoL_NNP =_SYM quality_NN of_IN life_NN ;_: SAPS_NNP =_SYM
        Simplified_NNP Acute_NNP Physiology_NNP Score_NN ._.
      
    
  
